OTCMKTS:DCTHD - Delcath Systems Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.11 +0.09 (+2.98 %)
(As of 07/19/2018 03:30 AM ET)
Previous Close$3.02
Today's Range$2.75 - $3.11
52-Week Range$1.22 - $63,000.0030
Volume14,230 shs
Average Volume79,871 shs
Market Capitalization$2.69 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.61
Delcath Systems logoDelcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive DCTHD News and Ratings via Email

Sign-up to receive the latest news and ratings for DCTHD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:DCTHD
CUSIPN/A
Phone212-489-2100

Debt

Debt-to-Equity RatioN/A
Current Ratio0.43
Quick Ratio0.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.71 million
Price / Sales1.03
Cash FlowN/A
Price / CashN/A
Book Value($6.91) per share
Price / Book-0.45

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-45,110,000.00
Net Margins-993.88%
Return on EquityN/A
Return on Assets-275.35%

Miscellaneous

Employees46
Outstanding Shares900,000
Market Cap$2.69

The Truth About Cryptocurrencies

Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions

What is Delcath Systems' stock symbol?

Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD."

When did Delcath Systems' stock split? How did Delcath Systems' stock split work?

Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) announced its quarterly earnings data on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, topping the Zacks' consensus estimate of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter. During the same period last year, the company posted ($686.00) EPS. View Delcath Systems' Earnings History.

What is the consensus analysts' recommendation for Delcath Systems?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Delcath Systems' key competitors?

Who are Delcath Systems' key executives?

Delcath Systems' management team includes the folowing people:
  • Roger G. Stoll Ph.D., Chairman of the Board (Age 74)
  • Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)
  • John Purpura, Executive Vice President - Global Head of Operations (Age 55)
  • Simon C. Pedder Ph.D., Director (Age 56)
  • William Dodge Rueckert, Independent Director (Age 64)
  • Marco Taglietti M.D., Independent Director (Age 57)

Has Delcath Systems been receiving favorable news coverage?

Media headlines about DCTHD stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Delcath Systems earned a coverage optimism score of 0.20 on Accern's scale. They also assigned media headlines about the medical device company an impact score of 46.36 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Delcath Systems?

Shares of DCTHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Delcath Systems' stock price today?

One share of DCTHD stock can currently be purchased for approximately $3.11.

How big of a company is Delcath Systems?

Delcath Systems has a market capitalization of $2.69 million and generates $2.71 million in revenue each year. Delcath Systems employs 46 workers across the globe.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The medical device company can be reached via phone at 212-489-2100 or via email at [email protected]


MarketBeat Community Rating for Delcath Systems (OTCMKTS DCTHD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe DCTHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCTHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.